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Abstract 
GLP-1(7-36)amide is an insulinotropic peptide derived from the intestinal post-translational proglucagon process, the release of which is increased 
mainly after a carbohydrate meal; also, its anti-diabetogenic effect in normal and diabetic states has been reported. In this study, GLP-1(7-36)amide 
stimulates the formation of glycogen from glucose in isolated rat hepatocytes, uch a glycogenic effect being achieved with physiological concentrations 
of the peptide. The GLP-1(7-36)amide-induced glycogenesis abolished by glucagon, and it is accompanied by stimulation of the glycogen synthase 
a activity and by a decrease in the basal and glucagon-stimulated cyclic AMP content. These findings could explain, at least in part, the GLP-I (7- 
36)amide insulin-independent plasma glucose lowering effect. 
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1. Introduction 
Glucagon-like peptide 1 (GLP-1) is an intestinal post- 
translational proglucagon product found in four vari- 
ants: proglucagon-78-108, or GLP-1(7-37), pro- 
glucagon-72-108, or GLP-l(l-37), and their respective 
amidated forms. The short forms, major products of the 
intestinal proglucagon molecule released during glucose 
absorption, are glucose-dependent insulinotropic (see [1] 
for review). The reported lack of effect of GLP-1(1-37) 
and GLP-1(7-37) on cyclic AMP formation, and the 
absence of glucagon-like effects (glycogenolysis and glu- 
coneogenesis) on rat hepatic glucose metabolism [2-4], 
supported the general believe that, except in the fish [5], 
GLP-1 was without effect on the carbohydrate liver me- 
tabolism (see [6] for review). Yet, the recent reported 
anti-diabetogenic effect of GLP-1(7-36)amide and GLP- 
1(7-37) [7,8] prompted us to explore the liver as a possi- 
ble site for extrapancreatic effects of these peptides on 
glucose disposal. We have studied the effect of GLP-1s 
on glycogen synthesis in isolated rat hepatocytes. 
Chemical Co. (St. Louis, MO), and Collagenase A from Clostridium 
histolyticum was from Boehringer-Mannheim GmbH (Mannheim, 
Germany). Protein assay kits (Bio-Rad protein assay) were from Bio- 
Rad Laboratories (Munich, Germany); Rianen CAMP [?]RIA kits 
were from DuPont Co. (Brussels, Belgium). o-[U-‘4C]glucose and D-[5- 
‘HIglucose were from Amersham (Little Chalfont, UK), and Ultima 
Gold scintillation liquid was from Packard (Groningen, The Nether- 
lands). 
2.3. Glycogen synthesis studies 
We have examined the incorporation of o-[U-‘4C]glucose into cellu- 
lar glycogen accordingly to the procedure described by Fleig et al. [9], 
in isolated hepatocytes prepared as in Hue et al. [IO]. Cells were first 
resuspended in Krebs-Ringer bicarbonate buffer (118 mM NaCI, 4.8 
mM KCI, 1.2 mM KH,PO,, 1.2 mM MgSO,, 2.5 mM CaCI,, and 25 
mM HNaCO,), pH 7.4 (KRB), containing 10 mM o-glucose, and then 
preincubated for 30 min at 37°C; after, I x lo6 hepatocytes were incu- 
bated for 30 min in 300 ~1 KRB, containing 0.05% BSA (bovine serum 
albumin), with 0.75 &i [U-‘4C]glucose at 20 mM o-glucose (or other- 
wise stated), in the absence or presence of insulin, GLP-1s and/or 
glucagon. 
2.4. Glycogen-synthase a and -phosphorylase a activities 
Isolated overnight fasted rat hepatocytes (4 x 106), previously prein- 
cubated for 15 min at 37°C in KRB containing 5.6 mM o-glucose, were 
incubated for 10 min in 100 ~1 KRB, containing 0.05% BSA and 16.7 
mM glucose, in the absence or presence of 10e9 M GLP-1(7-36)amide, 
10e9 M insulin and/or 10m9 M glucagon; the cells were immediately 
homogenized and frozen until the enzymes activities were assayed as 
in Hue et al. [lo] except hat the final glycogen extraction was as in Fleig 
et al. [9]. 
2. Materials and methods 2.5. Cyclic AMP 
2.1. Animals 
Fed Wistar rats, weighing 150-200 g, and kept on a standard pellet 
diet (UAR, Panlab, Spain) with tap water ad libitum. 
2.2. Chemicals 
Synthetic GLP-I (I-36)amide (lot no. 018862), GLP-1(7-36)amide 
(lot no. 010448), GLP-l(l-37) (lot no. 031790) and GLP-1(7-37) (lot 
no. 019860), were obtained from Peninsula Lab. Inc. (Belmont, CA). 
Crystalline pork glucagon (lot no. 2587 N646) was a gift from Eli Lilly 
Co. (Indianapolis, IN). Rat insulin (lot no. 220891) was from Novo 
BioLabs (Bagsvaerd, Denmark). BSA (Fraction V) was from Sigma 
We have examined the cyclic AMP content in rat hepatocytes after 
3 min incubation at 37” C, in the presence of lo-’ M amidated GLP-1s 
or insulin, alone or in combination with 10m9 M glucagon, while in the 
absence or presence of I mM IBMX. For that, after a preincubation 
period as in for glycogen synthesis, cells (3 x 10’) were incubated in 200 
~1 KRB buffer, pH 7.4, containing 10 mM o-glucose and 0.05% BSA, 
for 3 min at 37”C, in the absence or presence of IBMX (1 .O mM) and 
the given peptides. The incubation was stopped by the addition of 800 
~1 cold 81.25% ethanol; after mixing, each sample was centrifuged, and 
the corresponding supematant was evaporated and reconstituted for 
cyclic AMP radioimmunoassay. 
2.6. Statistical study 
*Corresponding author. Fax: (34) (1) 544-0247. 
Results are expressed as mean f S.E.M. Statistical significance of the 
increments was assessed by the Student’s t-test. Analysis of variance 
was also performed when appropriate. 
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3. Results 
3. I. Glycogen synthesis 
As shown in Fig. 1, the incorporation of glucose into 
hepatocyte glycogen, after 30 min incubation, was signif- 
icantly increased by GLP-1(7-36)amide (P < 0.001, 
F = 17.5, df = 50, as determined by analysis of variance) 
and by GLP-l(l-36)amide (P < 0.001, F= 19.9, 
df = 51) as well as by insulin (P < 0.001, F= 19.5, 
df = 91). The maximal increment in glycogen formation 
by GLP-1(7-36)amide or GLP- 1 (l-36)amide was 
achieved at lo-” M, whereas by insulin it was at lo-’ M. 
The lower concentration at which a significant effect was 
observed was lo-l2 M for GLP-1(7-36)amide (P < 0.01, 
R = 2, by the Newman-Keuls test) and for GLP-l(l- 
36)amide (P c 0.01, R = 2) while, for insulin, it was lo-” 
M (P < 0.01, R = 4); the ED,O was close to lo-l2 M for 
both amidated GLP-1 forms, and to lo-” M for insulin. 
The values reached with lo-l2 M to 10m9 M GLP-1(7- 
36)amide were significantly higher than those with insu- 
lin at the same respective doses (lo-l2 M and lo-” M, 
P c 0.001, df = 16; lo-” M and 10m9 M, P < 0.05, 
df = 18 and 27, by the Student’s t-test); essentially, the 
same was observed with GLP-l(l-36)amide (lo-l2 M 
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Fig. 1. Incorporation of o-[U-‘4C]glucose into rat hepatocyte glycogen. 
Effect of rat insulin, GLP-1(7-36)amide and GLP-I( I-36)amide. Mean 
values ( f S.E.M.) correspond to that of individual observations from 
2-6 separate hepatocyte preparations, each set up in, at least, duplicate. 
Values are expressed as the percentage of the mean value obtained in 
the absence of added peptides within the same experiment (6.4 k 0.3 
nmol/mg in 30 min, n = 18). 
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Fig. 2. Effect of 1O-9 M glucagon alone and in combination with IO-’ 
M other peptides on glycogen synthesis in rat hepatocytes. Mean values 
( f S.E.M.) correspond to that of individual observations from 2-6 
separate hepatocyte preparations, each set up in, at least, triplicate. 
Values are expressed as nmol of glucose incorporated into glycogen, per 
mg cell protein, in 30 min. 
and lo-” M, PC 0.001, df = 19 and 17; lo-” M, 
P < 0.01, df = 22; 1O-9 M, P > 0.05, df = 29). 
As shown in Fig. 2, glucagon at 10m9 M inhibited the 
basal glycogen formation (P c 0.01, df = 6, by the Stu- 
dent’s t-test) and abolished that induced by 10m9 M insu- 
lin (P < 0.001, df = 24) GLP-1(7-36)amide (p < 0.001 
d.f = 17) or GLP-1(1-36)amide (P < 0.001, df = 15). 
A significant glycogenic effect (P < 0.05 or more) of 
both amidated GLP-1 forms (10e9 M), as well as that of 
insulin, was also observed when glucose in the medium 
was lowered to 5 and 10 mM glucose (Fig. 3). 
When glycogen synthesis was stimulated by combined 
submaximal doses (1 O-” M) of insulin (130 k 11% of 
basal, n = 16) and either GLP-1(7-36)amide (156 f 13%, 
n = 9) or GLP-1(1-36)amide (156 f 34%, IZ = 9) the ef- 
fect was additive (190 f 18%, n = 17 and 185 f 32%, 
n = 18, respectively), whereas maximal effective doses 
( low8 M), tested in combination, did not elicit any further 
increment. 
The non-amidated forms of GLP-1 were tested at 10m8 
M, and they also showed to elicit a significant increment 
in glycogen synthesis, being 125 + 9% of basal (n = 27, 
P c 0.01) and 134 + 7% (n = 25, P < O.OOl), for GLP- 
l(l-37) and GLP-1(7-37), respectively, both values 
lower than that achieved by lo-’ M insulin (160 f 12%, 
n = 28) tested in parallel in seven individual experiments. 
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Fig. 3 Effect of glucose on the incorporation of o-[U-‘4C]glucose into 
rat hepatocyte glycogen. Peptides were all added at 10m9 M. Mean 
values ( + S.E.M.) correspond to one experiment set up in triplicate. 
Values are expressed as nmol of glucose incorporated into glycogen, per 
mg cell protein, in 30 min. 
3.2. Glycogen-synthase a and -phosphorylase a activity 
In 10 min incubation, GLP-1(7-36)amide, at 10F9 M, 
significantly increased (P < 0.001, n = 10 individual ex- 
periments, each set up in triplicate) the synthase a activ- 
ity to 154 f. 9% of the value obtained in the absence of 
peptide within the same experiment (0.148 + 0.017 units/ 
g of protein, n = lo), and this response was higher 
(P < 0.05) than that of 1O-9 M insulin (124 ? 7%, n = 5 
experiments run in parallel); 10m9 M glucagon alone in- 
hibited the basal synthase a activity to 77 k 7%, n = 6, 
P < 0.05, and when in combination with 10m9 M GLP- 
1(7-36)amide or insulin, the respective values obtained 
were not different from the basal (90 f 8% of basal and 
89 f 8%, n = 6 both groups). No significant changes of 
the basal value (25 + 3, n = 10, unit/g of protein) were 
detected in the phosphorylase a activity except with 10e9 
M glucagon (118 f 4%, n = 10, P < 0.01; the values ob- 
tained when glucagon was combined with 10m9 M GLP- 
1(7-36)amide or insulin, were not different from that of 
the basal (106 + 3% of basal and 102 &- 8, n = 6 both 
groups). 
3.3. Cyclic AMP 
It was observed (Table 1) that, in the absence of 
IBMX, the basal and glucagon-stimulated hepatocytes 
cyclic AMP content were significantly reduced by the 
presence of GLP-1(7-36)amide or GLP-1(1-37)amide, 
as it occurred with insulin, while that was not observed 
when IBMX was present. The non-amidated peptides, 
tested in the absence of IBMX, also significantly reduced 
the glucagon-stimulated cyclic AMP content. 
4. Discussion 
GLP-1(7-36)amide and GLP-l( l-37)amide showed to 
have in isolated rat hepatocytes a potent glycogenic ac- 
tion which, at least in the case of GLP-1(7-36)amide, was 
accompanied by an increase in glycogen synthase a activ- 
ity, being both effects abolished by glucagon; the non- 
amidated forms also had, to some extent, a glycogenic 
effect. Furthermore, these peptides reduced, in the ab- 
sence of IBMX, the glucagon-stimulated hepatocyte cy- 
clic AMP content; in addition, the amidated forms also 
reduced the basal content. 
These results indicate a direct glycogenic effect on rat 
hepatocytes of the four variants of GLP-1; among them, 
at least GLP-1(7-36)amide, which is known to be re- 
leased after a carbohydrate meal, exerted this effect at 
Table 1 
Effect of GLP-1 peptides upon cyclic AMP production in isolated fed rat hepatocytes 
Peptides Glucagon 
lO-8 M 1O-9 M 
Cyclic AMP production, percentage of control 
No IBMX Pvs. a P vs. b IBMX P vs. a P vs. b 
_ - 100.0 zk 6.3 (10) 100.0 f 12.0 (8) 
+ 170.3 f 6.7 (IO)” <O.OOl 580.3 + 67.1 (8)” c 0.001 
Insulin _ 71.8 f 4.6 (6) < 0.05 88.1 f 7.4 (8) >O.l 
Insulin + 119.0 +_ 12.4 (6) co.1 <O.Ol 568.4 f 38.0 (8) < 0.001 >O.l 
GLP-1(7-36) amide - 74.0 f 5.7 (7) co.05 92.0 +_ 6.4 (7) BO.1 
GLP- 1(7-36) amide + 122.4 + 1 I .O (7) co.1 co.01 487.0 f 25.1 (8) <O.OOl >O.l 
GLP-l(l-36) amide _ 67.8 + 4.2 (6) co.01 95.0 f 8.7 (8) >O.l 
GLP-l(l-36) amide + 129.4 + 13.2 (5) co.1 co.01 543.3 f 40.7 (6) < 0.001 >O.l 
GLP-I(7737) - 114.4 f 10.0 (5) 20.1 
GLP-1(7-37) + 135.4 It 13.9 (5) <O.Ol co.05 
GLP-l(l-37) - 99.4 f 9.2 (5) 20.1 
GLP-l(l-37) + 134.6 f 10.6 (5) < 0.05 co.05 
The data (mean + S.E.M., followed by the number of samples in parenthesis) are expressed as the percent of the respective mean control value in 
the absence (2.0 pmol/mg) or presence of IBMX (2.7 pmollmg). 
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physiological concentrations [I I-131. The increase in 
glycogen synthesis was accompanied by a stimulation of 
the synthase a activity and by a decrease of the cyclic 
AMP content only in the absence of IBMX, which indi- 
cates that a stimulation of a cyclic AMP phosphod- 
iesterase activity occurs; hence, the last steps in the mech- 
anism of the glycogenic effect of GLP-Is could be the 
same as that of insulin. On the other hand, we have 
evidence for the presence of specific binding of the ami- 
dated peptides can be detected in hepatocytes plasma 
membranes, which does not show binding with insulin or 
glucagon [14]; thus, if the effect of GLP-Is in the liver 
occurs through specific receptors, those could be differ- 
ent to that described for GLP-1(7-36)amide in pancre- 
atic B cells [ 151, in which the insulinotropic action of the 
peptide is associated with an activation of adenylate 
cyclase [16,17]. We believe that GLP-1(7-36)amide may 
play a physiological and physiopathological role (i.e. 
diabetes mellitus) at the level of the glucose storage in the 
liver, which could explain, at least in part, its insulin- 
independent plasma glucose lowering effect. 
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